CCCC C4 Therapeutics, Inc.
XNAS
3.17
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CCCC
$3.17
—
Key stats
$3.17
Pre-market
$3.17
+0.00%
- 52-Week Range
- $1.69 – $5.17
- YTD
- +64.25%
- IV Rank (30D)
- 74.6
- Straddle Price
- $0.97
- P/C Vol Ratio
- 0.28
- Market Cap
- $0.4B
- Open
- $3.15
- Day Range
- $3.10 – $3.22
- Volume
- 2,189,796
- Prev Close
- $3.16
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.96 |
| Cost of Equity (CAPM) | 15.96% (VRP-adj) |
| WACC | 15.94% |
| Volatility Risk Premium | +63.6pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -41.0% |
| Book / Price | 69.9% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -243.7% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $3.45 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.98 |
| Bollinger Width / SMA20 | 795.5% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: INGN, MYGN, PCRX
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
86%
20-Day Fair Value
≈ by Nov 20, 2026
$3.19
α +0.6%
rank 59%
conviction
40%
40-Day Fair Value
≈ by Dec 21, 2026
$3.30
α +4.0%
rank 63%
conviction
95%
60-Day Fair Value
≈ by Jan 19, 2027
$3.28
α +3.3%
rank 59%
conviction
86%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $3.85 | 50% | median 1.7× · 3 peers |
| Peer P/S | $0.21 | 50% | median 0.7× · 3 peers |
| Market Anchor (SMA50) | $3.45 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $2.92 | 0% | 5 strikes · skew -0.35 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.4B
- Employees
- 104
- List Date
- 2020-10-02
- CIK
- 0001662579
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- ($0.20) (3 est.)
- Headquarters
- Watertown, MA
- Homepage
- https://www.c4therapeutics.com
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the pot…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 13.02% | -26.48% | 22.10% | -5.21% | -5.19% | -1.55% | -0.55% |
| Feb | 12.80% | -12.38% | -33.38% | 89.97% | -19.35% | 43.62% | 13.55% |
| Mar | -12.74% | 6.59% | -37.76% | -25.66% | -33.33% | -17.03% | -19.99% |
| Apr | -14.32% | -65.80% | -5.63% | -22.22% | 14.29% | 4.81% | -14.81% |
| May | 9.87% | -22.52% | 4.63% | -23.55% | -23.31% | 49.66% | -0.87% |
| Jun | 1.01% | 15.47% | -18.15% | -4.55% | 7.52% | 6.62% | 1.32% |
| Jul | 11.16% | 20.05% | 37.46% | 38.14% | 35.76% | -19.35% | 20.54% |
| Aug | -10.42% | 6.33% | -21.83% | -5.39% | 22.64% | 6.00% | -0.44% |
| Sep | 6.31% | -13.51% | -35.42% | -5.16% | -11.55% | -13.95% | -12.21% |
| Oct | -3.35% | 10.70% | -12.35% | -4.14% | 21.40% | 0.96%* | 2.20% |
| Nov | -19.27% | -16.31% | 23.48% | -18.89% | 9.27% | -- | -4.34% |
| Dec | -6.37% | -29.93% | 253.13% | -16.28% | -24.80% | -- | 35.15% |
| Total | -18.19% | -84.94% | 8.52% | -38.70% | -29.42% | 45.72% | -19.50% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.98
SMA 50: $3.45
SMA 200: $3.17
Current: $3.17
EMA 12: $2.98
EMA 26: $3.09
MACD: -0.1181 | Signal: 0.0494
BEARISH
ADX (14): 19.77
RANGE
+DI: 27.55
−DI: 24.51
Momentum Oscillators
RSI (14): 52.11
NEUTRAL
Stoch %K: 63.31
Stoch %D: 45.46
Williams %R: -21.62
Volume & Volatility
BB Upper: $3.33
BB Lower: $2.63
NEUTRAL
OBV: -37,870,519
Vol SMA 20: 2,568,517
Vol ROC: -3.48%
ATR: $0.22
True Range: $0.12
HV 20: 85.1%
HV 30: 73.6%
HV 60: 63.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers:
- Recent positive news headlines highlighting company milestones, conference participations, and business highlights
- Bullish momentum signals from technical indicators, including MACD and RSI
Primary Risks:
- High volatility and beta, indicating a high-risk stock
- Potential for significant price movements based on options market expectations
Investment Thesis: CCC is a high-growth biotech company with a strong track record of advancing its pipeline. Recent news highlights the company's strategic milestones, which could drive further growth.
Recent News Sentiment Impact: Positive news headlines have contributed to the stock's upward momentum, supporting our bullish assessment.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Uptrend
- Long-term (3-12 months): Uptrend
Support/Resistance Levels:
- SMA 20: $4.17 (support)
- SMA 50: $3.75 (resistance)
- Upper Bollinger Band: $4.60 (resistance)
Momentum Signals:
- RSI: 49.69 (neutral, but trending upwards)
- MACD: Bullish momentum signal
- Bollinger Bands: Neutral
Volume Analysis:
- Volume SMA 20: 4003577.75 (increasing volume supports trend)
- On-Balance Volume (OBV): -36367478.83 ( bearish sentiment in OBV, but increasing volume contradicts)
News & Sentiment Analysis
Recent Headlines Summary: Recent news highlights the company's strategic milestones, conference participations, and business highlights.
Sentiment Assessment: Positive
Catalyst Identification:
- Upcoming conferences and events
- Product launches and pipeline updates
Market Narrative: Positive news sentiment aligns with technical signals, supporting our bullish assessment.
Risk & Volatility Assessment
Beta Interpretation: CCC has a high beta of 1.90, indicating it is more volatile than the market.
Volatility Regime: The current volatility regime is high, with stock moves exceeding market movements.
Options Market Signals: IV Rank: Low (shows historically low volatility) Current IV: 143.9% (high volatility) Expected Move: $1.10 (42 DTE), 7-DTE: $0.35
Downside Protection: Support levels and risk management considerations are crucial in this high-volatility environment.
Market Context & Positioning
Sector Performance: CCC is outperforming its sector, which is a positive sign.
Institutional Activity: Increasing institutional interest supports the trend.
Correlation Analysis: The stock has a low correlation with the market (R-squared interpretation), indicating it may move independently of the broader market.
Relative Valuation: CCC is relatively undervalued within its trading range.
Key Levels & Action Items
Critical Price Levels:
- Support: SMA 20 ($4.17)
- Resistance: Upper Bollinger Band ($4.60)
Breakout/Breakdown Levels: No specific levels mentioned, but the stock may break out above $4.60 or below $3.74.
Time-Sensitive Catalysts: Upcoming conferences and events, product launches, and pipeline updates.
Risk Management: Stop-loss levels and position sizing considerations are crucial in this high-volatility environment.
By analyzing the data and news sentiment, we believe CCC is a high-growth biotech company with significant upside potential. However, investors should be aware of the stock's high volatility and beta, which may result in significant price movements. A bullish momentum signal from technical indicators supports our assessment, but caution is advised due to the high-risk nature of the stock.
Generated
News
All CCCC news →
Earnings History
14 of 16 under expected move
Avg Expected Move
55.76%
Avg Actual Move
3.54%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-01-10 | After-Close | 3.23% | 4.83% | 1.50x | Exceeded |
| 2022-05-05 | After-Close | 43.18% | 4.20% | 0.10x | Within |
| 2022-08-04 | After-Close | 6.41% | 9.15% | 1.43x | Exceeded |
| 2023-05-04 | After-Close | 24.46% | 1.86% | 0.08x | Within |
| 2023-08-08 | After-Close | 31.34% | 1.42% | 0.05x | Within |
| 2023-11-01 | After-Close | 93.18% | 6.06% | 0.07x | Within |
| 2024-05-08 | After-Close | 43.10% | 5.43% | 0.13x | Within |
| 2024-08-01 | Pre-Market | 26.12% | 0.30% | 0.01x | Within |
| 2024-10-31 | After-Close | 35.18% | 5.25% | 0.15x | Within |
| 2025-02-27 | Pre-Market | 124.53% | 1.89% | 0.02x | Within |
| 2025-05-07 | Pre-Market | 49.65% | 6.38% | 0.13x | Within |
| 2025-08-07 | After-Close | 26.16% | 3.10% | 0.12x | Within |
| 2025-11-06 | After-Close | 335.08% | 1.68% | 0.01x | Within |
| 2026-02-26 | After-Close | 24.28% | 2.88% | 0.12x | Within |
| 2026-05-13 | After-Close | 9.51% | 1.36% | 0.14x | Within |
| 2026-08-11 | After-Close | 16.80% | 0.78% | 0.05x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CCCC Options Activity & IV Rank
CCCC IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 136.3%
7-DTE IV: —
Expected Move: $0.97
7-DTE Move: $0.97
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 25
Put Volume: 7
P/C Volume: 0.28
BULLISH
Call OI: 459
Put OI: 243
P/C OI: 0.529
Total OI: 702
ATM Options Pricing
ATM Call: $0.60
ATM Put: $0.38
Call %: 18.9%
Put %: 11.8%
Chain Summary
Chain Volume: 4,076
Chain OI: 31,705
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 55th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
55%
vs own history
GEX tilt
+0.50
OI-weighted, today
Vanna tilt
+0.39
δ-sensitivity to IV
Charm tilt
-0.50
δ-decay vs time
Vanna tilt +0.39: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.50: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 6 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · ATM 136.3% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)74.6MediumOct 21
Straddle Price (30 DTE)$0.97Oct 21
Beta Analysis
Risk Metrics
Beta: 1.9580
Alpha: 28.49%
Correlation: 0.3048
R-Squared: 9.3%
Stock Volatility: 81.6%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CCCC
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $19.6M | #1166 of 6285 | +66.8% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $5.6M | #1402 of 3138 | -51.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $2.3M | #1317 of 4729 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $1.0M | #2904 of 3716 | -84.5% | 13F | |
| Point72 Hedge fund Steve Cohen | $812K | #1531 of 1945 | +2.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CCCC Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 111,627,586 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
9 filers$4.52M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Squadron Capital Management LLC | $1.87M | 41.28% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $1.21M | 26.76% | 2026-06-30 |
| 3 | Caption Management, LLC | $825.66K | 18.25% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $234.90K | 5.19% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $140.57K | 3.11% | 2026-06-30 |
| 6 | Citadel Advisors LLC Custodian | $114.88K | 2.54% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $99.47K | 2.20% | 2026-06-30 |
| 8 | Wolverine Trading, LLC Custodian | $28.99K | 0.64% | 2025-09-30 |
| 9 | Walleye Capital LLC | $1.40K | 0.03% | 2026-06-30 |
4 filers$619.24K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $336.71K | 54.37% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $178.86K | 28.88% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $80.79K | 13.05% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $22.88K | 3.70% | 2026-06-30 |
CCCC Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Donna Roy Grogan | Director | Award (A) | +4,618 | $3.14 | $14.5K | EDGAR |
| 2026-10-02 | Kenneth Carl Anderson | Director | Award (A) | +3,662 | $3.14 | $11.5K | EDGAR |
| 2026-09-21 | Kendra Adams | Chief Financial Officer | Mixed | +3,475 | $3.39 | -$9.4K | EDGAR |
| 2026-07-13 | Leonard Reyno | Chief Medical Officer | Mixed | +7,928 | $4.06 | -$30.0K | EDGAR |
| 2026-07-02 | Donna Roy Grogan | Director | Award (A) | +3,341 | $4.34 | $14.5K | EDGAR |
| 2026-07-02 | Kenneth Carl Anderson | Director | Award (A) | +2,650 | $4.34 | $11.5K | EDGAR |
| 2026-06-26 | Ronald Harold Wilfred Cooper | Director | Grant (A) | +62,000 opt | — | EDGAR | |
| 2026-06-26 | Donna Roy Grogan | Director | Grant (A) | +62,000 opt | — | EDGAR | |
| 2026-06-26 | Utpal Koppikar | Director | Grant (A) | +62,000 opt | — | EDGAR | |
| 2026-06-26 | Laura Bessen | Director | Grant (A) | +62,000 opt | — | EDGAR | |
| 2026-06-26 | Owen Hughes | Director | Grant (A) | +62,000 opt | — | EDGAR | |
| 2026-06-26 | Stephen Fawell | Director | Grant (A) | +62,000 opt | — | EDGAR | |
| 2026-06-26 | Kenneth Carl Anderson | Director | Grant (A) | +62,000 opt | — | EDGAR | |
| 2026-06-26 | Steven L. Hoerter | Director | Grant (A) | +62,000 opt | — | EDGAR | |
| 2026-06-04 | Kenneth Carl Anderson | Director | Exer (M) | +1,070 | $2.11 | $2.3K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CCCC Insider Holdings
11 insiders · @ $3.17
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Andrew Hirsch | President & CEO | 1,123,145 | $3.56M | $84.0K | 15 | 2026-02-18 |
| 2 | Kendra Adams | Chief Financial Officer | 382,323 | $1.21M | $0 | 10 | 2026-09-21 |
| 3 | Leonard Reyno | Chief Medical Officer | 379,803 | $1.20M | -$22.2K | 9 | 2026-07-13 |
| 4 | Paige Mahaney | Chief Scientific Officer | 336,910 | $1.07M | $0 | 4 | 2026-02-18 |
| 5 | Kelly Schick | Chief People Officer | 308,885 | $979.2K | $0 | 12 | 2026-02-18 |
| 6 | Scott N Boyle | Chief Business Officer | 306,070 | $970.2K | -$3.7K | 12 | 2026-02-18 |
| 7 | Kenneth Carl Anderson | Director | 205,489 | $651.4K | $0 | 37 | 2026-10-02 |
| 8 | Donna Roy Grogan | Director | 79,471 | $251.9K | $0 | 22 | 2026-10-02 |
| 9 | Mark Mossler | Chief Accounting Officer | 75,184 | $238.3K | $0 | 3 | 2026-02-18 |
| 10 | Jolie Siegel | Chief Legal Officer | 54,353 | $172.3K | -$1.19M | 15 | 2025-02-18 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CCCC Board & Officers
As of SEC filings through Oct 2, 2026Directors 9
- Andrew Hirsch · since Oct 1, 2020
- Kenneth Carl Anderson · since Oct 1, 2020
- Utpal Koppikar · since Mar 16, 2022
- Donna Roy Grogan · since Jul 29, 2022
- Laura Bessen · since Jul 29, 2022
- Owen Hughes · since Nov 16, 2023
- Ronald Harold Wilfred Cooper · since Jun 7, 2024
- Stephen Fawell · since Aug 29, 2024
- Steven L. Hoerter · since Nov 19, 2024
Officers 6
- Andrew Hirsch · President & CEO · since Oct 1, 2020
- Kendra Adams · Chief Financial Officer · since Sep 18, 2023
- Kelly Schick · Chief People Officer · since Mar 16, 2022
- Scott N Boyle · Chief Business Officer · since Mar 16, 2022
- Leonard Reyno · Chief Medical Officer · since Jul 10, 2023
- Paige Mahaney · Chief Scientific Officer · since Oct 28, 2024
Changes in the last 10 years (42)
| May 12, 2026 | The company announced the departure of Mark Mossler as Chief Accounting Officer in an SEC filing |
| Apr 10, 2025 | The company announced the departure of Bruce Downey from the board in an SEC filing |
| Nov 19, 2024 | Steven L. Hoerter became a director |
| Oct 28, 2024 | Paige Mahaney became Chief Scientific Officer |
| Oct 1, 2024 | The company announced the departure of Stewart Fisher as Chief Scientific Officer in an SEC filing |
| Aug 29, 2024 | Stephen Fawell became a director |
| Aug 28, 2024 | The company announced the departure of Malcolm Salter from the board in an SEC filing |
| Jun 7, 2024 | Ronald Harold Wilfred Cooper became a director |
| Jun 6, 2024 | The company announced the departure of Glenn Dubin from the board in an SEC filing |
| Nov 16, 2023 | Owen Hughes became a director |
| Sep 18, 2023 | Mark Mossler became Chief Accounting Officer |
| Sep 18, 2023 | Kendra Adams became Chief Financial Officer |
| Aug 30, 2023 | The company announced the departure of Lauren White as Chief Financial Officer in an SEC filing |
| Jul 10, 2023 | Leonard Reyno became Chief Medical Officer |
| Jan 30, 2023 | The company announced the departure of Adam Crystal as Chief Medical Officer in an SEC filing |
| Jul 29, 2022 | Laura Bessen became a director |
| Jul 29, 2022 | Donna Roy Grogan became a director |
| Mar 16, 2022 | Utpal Koppikar became a director |
| Mar 16, 2022 | Scott N Boyle became Chief Business Officer |
| Mar 16, 2022 | Kelly Schick became Chief People Officer |
| Mar 10, 2022 | The company announced the departure of Elena Prokupets from the board in an SEC filing |
| Jun 21, 2021 | Lauren White became Chief Financial Officer |
| Jun 14, 2021 | Marc A Cohen no longer listed as a 10% owner in SEC filings |
| Jun 14, 2021 | Alain J Cohen no longer listed as a 10% owner in SEC filings |
| Mar 12, 2021 | Glenn Dubin became a director |
| Oct 5, 2020 | Marc A Cohen no longer listed as Chief Executive Officer in SEC filings |
| Oct 1, 2020 | William McKee became Chief Financial Officer |
| Oct 1, 2020 | Stewart Fisher became Chief Scientific Officer |
| Oct 1, 2020 | Marc A Cohen became a director |
| Oct 1, 2020 | Marc A Cohen became a 10% owner |
| Oct 1, 2020 | Marc A Cohen became Chief Executive Officer |
| Oct 1, 2020 | Malcolm Salter became a director |
| Oct 1, 2020 | Laura Jean Wahlberg became VP of Finance Corp Controller |
| Oct 1, 2020 | Kenneth Carl Anderson became a director |
| Oct 1, 2020 | Jolie Siegel became Chief Legal Officer |
| Oct 1, 2020 | Elena Prokupets became a director |
| Oct 1, 2020 | Bruce Downey became a director |
| Oct 1, 2020 | Andrew Hirsch became a director |
| Oct 1, 2020 | Andrew Hirsch became President & CEO |
| Oct 1, 2020 | Alain J Cohen became a director |
| Oct 1, 2020 | Alain J Cohen became a 10% owner |
| Oct 1, 2020 | Adam Crystal became Chief Medical Officer |
Not reported recently (5)
- Jolie Siegel · Last reported as Chief Legal Officer in an SEC filing dated Feb 18, 2025
- Marc A Cohen · Last reported as a director in an SEC filing dated Jun 23, 2022
- Alain J Cohen · Last reported as a director in an SEC filing dated Apr 5, 2022
- Laura Jean Wahlberg · Last reported as VP of Finance Corp Controller in an SEC filing dated Feb 16, 2021
- William McKee · Last reported as Chief Financial Officer in an SEC filing dated Oct 6, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CCCC Proposed Insider Sales (Form 144)
Latest: 2026-08-14
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
4 filings
· $155K notice value
· 2 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Mark Mossler (3, $155K) · JAY GELDMACHER (1)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Mark Mossler | Officer | 4,139 | $17.6K | 2026-08-14 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-14 | JAY GELDMACHER | Former REZI CEO | 82,563 | — | 2026-08-14 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-13 | Mark Mossler | Officer | 15,000 | $61.1K | 2026-08-13 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-12 | Mark Mossler | Officer | 19,519 | $76.7K | 2026-08-12 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-28 | Mark Mossler | Former Section 16 Officer | 9,087 | $35.5K | 2026-05-27 | E*Trade | — | EDGAR |
| 2026-03-09 | JOLIE M SIEGEL | Officer | 101,175 | $378.8K | 2026-03-09 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-11-18 | Salter Malcolm | Director | 13,000 | $54.5K | 2024-11-18 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-10-18 | Salter Malcolm | Director | 13,000 | $83.3K | 2024-10-18 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-10-11 | Salter Malcolm | Director | 8,561 | $46.1K | 2024-10-11 | MORGAN STANLEY SMITH BARNEY LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
33 ETFs hold CCCC
25 shown · $43.66M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $10.9M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $8.3M | $75.1B | 2026-10-20 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $4.0M | — | 2026-09-30 |
| 4 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.05% | $3.4M | $6.6B | 2026-10-20 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $2.9M | $13.7B | 2026-10-20 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.02% | $2.7M | $11.0B | 2026-10-20 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $2.0M | — | 2026-09-30 |
| 8 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.6M | — | 2026-05-31 |
| 9 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $1.4M | — | 2026-10-20 |
| 10 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.07% | $1.3M | — | 2026-10-20 |
| 11 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.08% | $968,098 | $1.2B | 2026-10-20 |
| 12 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $893,221 | — | 2026-10-20 |
| 13 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.03% | $720,395 | — | 2026-07-31 |
| 14 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.01% | $694,603 | — | 2026-10-20 |
| 15 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.02% | $614,607 | $3.1B | 2026-10-20 |
| 16 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $311,015 | — | 2026-09-30 |
| 17 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $166,545 | — | 2026-10-20 |
| 18 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $156,173 | — | 2026-10-21 |
| 19 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $149,003 | — | 2026-10-20 |
| 20 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $118,091 | — | 2026-05-31 |
| 21 | DFAU Dimensional US Core Equity Market ETF | Dimensional | 0.00% | $110,692 | $13.1B | 2026-10-20 |
| 22 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.48% | $98,314 | — | 2026-10-20 |
| 23 | DFUS Dimensional US Equity Market ETF | Dimensional | 0.00% | $72,731 | $21.4B | 2026-10-20 |
| 24 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $28,392 | — | 2026-09-30 |
| 25 | DFSU Dimensional US Sustainability Core 1 ETF | Dimensional | 0.00% | $26,873 | $2.4B | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.99
TTM Revenue
$35.04M
TTM Net Income
$-101.42M
TTM Op. Cash Flow
$-84.87M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $6.64M | $-23.64M | $-0.18 | $-1.57M |
| Q1 '26 | 2026-03-31 | $6.15M | $-25.13M | $-0.20 | $-29.94M |
| Q4 '25 | 2025-12-31 | $11.02M | $-20.49M | $-0.09 | $-22.14M |
| Q3 '25 | 2025-09-30 | $11.23M | $-32.17M | $-0.44 | $-31.21M |
| Q2 '25 | 2025-06-30 | $6.46M | $-26.02M | $-0.37 | $-12.06M |
| Q1 '25 | 2025-03-31 | $7.24M | $-26.32M | $-0.37 | $-33.28M |
| Q4 '24 | 2024-12-31 | $5.18M | $-34.57M | $-0.49 | $-17.93M |
| Q3 '24 | 2024-09-30 | $15.36M | $-24.67M | $-0.35 | $-24.13M |
| Q2 '24 | 2024-06-30 | $12.01M | $-17.72M | $-0.26 | $-4.97M |
| Q1 '24 | 2024-03-31 | $3.04M | $-28.36M | $-0.41 | $-18.12M |
| Q4 '23 | 2023-12-31 | $3.26M | $-34.75M | $-0.68 | $-24.01M |
| Q3 '23 | 2023-09-30 | $11.07M | $-27.04M | $-0.55 | $-30.71M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.43
P/S
10.10
EV/EBITDA
—
EV/Sales
7.86
ROE
-41.0%
ROA
-28.2%
Div Yield
0.00%
FCF Yield
-23.98%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$353.86M
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
40.40M
SI % of Float
40.99%
Days to Cover
17.65
Short Vol Ratio
38.4%
Free Float
98.54M
Float %
88.8%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14